Preparations had been made for the grand transformation of Bavarian Nordic when it acquired the travel vaccines Rabipur and Encepur from Glaxosmithkline in October 2019. Production, however, had barely begun when the Covid-19 pandemic hit.
"It definitely means something for us financially that we haven't gotten the revenue from the vaccines that we had hoped. It's a crossed-out section in the accounts. Across this year and the last, I would estimate that we've lost out on around EUR 100m solely because of Covid-19," EVP and Chief Financial Officer at Bavarian Nordic Henrik Juuel says, adding:
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.